The potential impact of coinfection on antimicrobial chemotherapy and drug resistance

Trends in Microbiology

Volumn 23, Issue 9, 2015, Pages 537-544

  Birger, Ruthie B ^a   Kouyos, Roger D ^b,c   Cohen, Ted ^d   Griffiths, Emily C ^e   Huijben, Silvie ^f   Mina, Michael ^a,g   Volkova, Victoriya ^h   Grenfell, Bryan ^a,i   Metcalf, C Jessica E ^a,i  

^a PRINCETON UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d YALE UNIVERSITY   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h KANSAS STATE UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Coinfection; Drug resistance; Immune modulation; Parasite interactions; Resource competition

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL VIRULENCE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG RESISTANCE; HELICOBACTER PYLORI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; INFLUENZA; INNATE IMMUNITY; INTRASPECIFIC COMPETITION; MALARIA; MIXED INFECTION; NONHUMAN; PATHOGEN LOAD; PLASMODIUM CHABAUDI; PREVALENCE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS; VIBRIO CHOLERAE; ANIMAL; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; COINFECTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; ORGANISMAL INTERACTION; PARASITOLOGY; PHYSIOLOGY;

ANIMALS; COINFECTION; DRUG RESISTANCE, MICROBIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; MICROBIAL INTERACTIONS; MODELS, BIOLOGICAL;

EID: 84940460691     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.05.002     Document Type: Review

References (100)

1. Antimicrobial Resistance: Global Report on Surveillance 2014 2014, World Health Organization, World Health Organization.
2. Juliano J.J., et al. Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20138-20143.
3. Pawlowski A., et al. Tuberculosis and HIV co-infection. PLoS Pathog. 2012, 8:e1002464.
4. Hernandez M.D., Sherman K.E. HIV/hepatitis C coinfection natural history and disease progression. Curr. Opin. HIV AIDS 2011, 6:478-482.
5. Van Geertruyden J-P., et al. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar. J. 2008, 7:134.
6. Flateau C., et al. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect. Dis. 2011, 11:541-556.
7. González R., et al. HIV and malaria interactions: where do we stand?. Expert Rev. Anti. Infect. Ther. 2012, 10:153-165.
8. Huijben S., et al. Aggressive chemotherapy and the selection of drug resistant pathogens. PLoS Pathog. 2013, 9:e1003578.
9. Bush L.M., et al. Resistant herpes simplex virus infection and HIV: a potential diagnostic and therapeutic dilemma. Lab. Med. 2011, 42:452-457.
10. Bifani P., et al. The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population. J. Infect. Dis. 2008, 198:90-94.
11. Pollitt L.C., et al. Rapid response to selection, competitive release and increased transmission potential of artesunate-selected Plasmodium chabaudi malaria parasites. PLoS Pathog. 2014, 10:e1004019.
12. Metzger D.W., Sun K. Immune dysfunction and bacterial coinfections following influenza. J. Immunol. 2013, 191:2047-2052.
13. Dye C., et al. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002, 295:2042-2046.
14. Diedrich C.R., Flynn J.L. HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?. Infect. Immun. 2011, 79:1407-1417.
15. Gurumurthy P., et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 2004, 38:280-283.
16. Menéndez C., et al. HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. Clin. Infect. Dis. 2011, 52:41-48.
17. Graham A.L. Ecological rules governing helminth-microparasite coinfection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:566-570.
18. Osborne L.C., et al. Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation. Science 2014, 345:578-582.
19. Kumagai T., et al. Virus specific cell-mediated immunity may play a role in controlling reactivated human herpesvirus 6B in patients under measles induced immunosuppression. J. Med. Virol. 2014, 86:658-665.
20. Gómez-Pérez G.P., et al. Plasmodium falciparum malaria and invasive bacterial co-infection in young African children: the dysfunctional spleen hypothesis. Malar. J. 2014, 13:335.
21. Taubenberger J.K., Kash J.C. Insights on influenza pathogenesis from the grave. Virus Res. 2011, 162:2-7.
22. Cohen T., et al. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin. Microbiol. Rev. 2012, 25:708-719.
23. Schmid-Hempel P. Parasite immune evasion: a momentous molecular war. Trends Ecol. Evol. 2008, 23:318-326.
24. Moens L., et al. Cross-protective immunity against heterologous Streptococcus pneumoniae. Infect. Immun. 2012, 80:1944-1945. author reply 1946.
25. Fairlie-Clarke K.J., et al. Quantifying variation in the potential for antibody-mediated apparent competition among nine genotypes of the rodent malaria parasite Plasmodium chabaudi. Infect. Genet. Evol. 2013, 20:270-275.
26. Lin D., Koskella B. Friend and foe: factors influencing the movement of the bacterium Helicobacter pylori along the parasitism-mutualism continuum. Evol. Appl. 2014, 8:9-22.
27. Kam Y., et al. Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance. Womens Health (Lond. Engl.) 2014, 10:423-430.
28. Kümmerli R., et al. Habitat structure and the evolution of diffusible siderophores in bacteria. Ecol. Lett. 2014, 17:1536-1544.
29. Griffen A., et al. Cooperation and competition in pathogenic bacteria. Nature 2004, 430:1024-1027.
30. Bosch A.A.T.M., et al. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013, 9:e1003057.
31. Weinberger D.M., et al. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. PLoS Med. 2015, 12:e1001776.
32. Klima C.L., et al. Characterization of Mannheimia haemolytica isolated from feedlot cattle that were healthy or treated for bovine respiratory disease. Can. J. Vet. Res. 2014, 78:38-45.
33. Siegel S.J., et al. Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe 2014, 16:55-67.
34. Pettigrew M.M., et al. Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza A virus infection. Infect. Immun. 2014, 82:4607-4619.
35. Marks L.R., et al. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. MBio 2013, 4:e00438-e513.
36. Wolcott R.D., et al. Evaluation of the bacterial diversity among and within individual venous leg ulcers using bacterial tag-encoded FLX and titanium amplicon pyrosequencing and metagenomic approaches. BMC Microbiol. 2009, 9:226.
37. Elias S., Banin E. Multi-species biofilms: living with friendly neighbors. FEMS Microbiol. Rev. 2012, 36:990-1004.
38. Huijben S., et al. The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection. J. Evol. Biol. 2011, 24:2410-2422.
39. Harrington W.E., et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9027-9032.
40. Raberg L., et al. The role of immune-mediated apparent competition in genetically diverse malaria infections. Am. Nat. 2006, 168:41-53.
41. Mideo N., et al. Understanding and predicting strain-specific patterns of pathogenesis in the rodent malaria Plasmodium chabaudi. Am. Nat. 2008, 172:214-238.
42. Metcalf C.J.E., et al. Partitioning regulatory mechanisms of within-host malaria dynamics using the effective propagation number. Science 2011, 333:984-988.
43. Kalsdorf B., et al. Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis. Eur. J. Immunol. 2013, 43:540-549.
44. Gonzalez V., et al. Innate immunity and chronic immune activation in HCV/HIV-1 coinfection. Clin. Immunol. 2010, 135:12-25.
45. Mideo N., Day T. On the evolution of reproductive restraint in malaria. Proc. Biol. Sci. 2008, 275:1217-1224.
46. Read A.F., Taylor L.H. The ecology of genetically diverse infections. Science 2001, 292:1099-1102.
47. Zur Wiesch P.A., et al. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 2011, 11:236-247.
48. Balmer O., Tanner M. Prevalence and implications of multiple-strain infections. Lancet Infect. Dis. 2011, 11:868-878.
49. Wacker M.A., et al. Quantification of multiple infections of Plasmodium falciparum in vitro. Malar. J. 2012, 11:180.
50. Volkova V.V., et al. Effects of broiler feed medications on Salmonella. Avian Dis. 2013, 57:640-644.
51. Song T., et al. Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β' subunit of RNA polymerase. Mol. Microbiol. 2014, 91:1106-1119.
52. Bjorkman J., et al. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000, 287:1479-1482.
53. Balmer O., et al. Intraspecific competition between co-infecting parasite strains enhances host survival in African trypanosomes. Ecology 2009, 90:3367-3378.
54. Margolis E., et al. The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competion and interactions with host's immune reponse. BMC Microbiol. 2010, 10:59.
55. Kouyos R.D., et al. The path of least resistance: aggressive or moderate treatment?. Proc. R. Soc. B 2014, 281:20140566.
56. + T lymphocytes. J. Gen. Virol. 2008, 89:984-993.
57. Ezenwa V.O., Jolles A.E. Opposite effects of anthelmintic treatment on microbial infection at individual versus population scales. Science 2015, 347:175-177.
58. Hansen J., Day T. Coinfection and the evolution of drug resistance. J. Evol. Biol. 2014, 27:2595-2604.
59. Fischer A., et al. The value of monitoring to control evolving populations. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:1007-1012.
60. Skrahina A., et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull. World Health Organ. 2013, 91:36-45.
61. Strauss O.J., et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 2008, 46:1514-1516.
62. Getahun H., et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 2010, 50(Suppl. 3):S201-S207.
63. Sergeev R., et al. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci. Transl. Med. 2012, 4:135ra67.
64. Griffiths E.C., et al. The nature and consequences of coinfection in humans. J. Infect. 2011, 63:200-206.
65. Jolles A.E., et al. Interactions between macroparasites and microparasites drive infection patterns in free-ranging African buffalo. Ecology 2008, 89:2239-2250.
66. Lass S., et al. Generating super-shedders: co-infection increases bacterial load and egg production of a gastrointestinal helminth. J. R. Soc. Interface 2013, 10:20120588.
67. Singer M. Introduction to Syndemics: a Critical Systems Approach to Public and Community Health 2009, John Wiley.
68. Gould F. Comparisons between resistance management strategies for insects and weeds. Weed Technol. 1995, 9:830-839.
69. Neve P., et al. Expanding the eco-evolutionary context of herbicide resistance research. Pest Manag. Sci. 2014, 70:1385-1393.
70. Vigueira C.C., et al. The red queen in the corn: agricultural weeds as models of rapid adaptive evolution. Heredity (Edinb). 2013, 110:303-311.
71. Tosh P.K., McDonald L.C. Infection control in the multidrug-resistant era: tending the human microbiome. Clin. Infect. Dis. 2012, 54:707-713.
72. Singh R., et al. Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin. Microbiol. Infect. 2014, 20:O977-O978.
73. Ling L.L., et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015, 517:455-459.
74. Bagasra O., et al. Hepatitis G virus or GBV-C: a natural anti-HIV interfering virus. Viruses: Essential Agents of Life 2012, 363-388. Springer. G. Witzany (Ed.).
75. Snounou G., Pérignon J-L. Malariotherapy - insanity at the service of malariology. Adv. Parasitol. 2013, 81:223-255.
76. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007, 153:917-923.
77. Iwase T., et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010, 465:346-349.
78. Cirimotich C.M., et al. Natural microbe-mediated refractoriness to Plasmodium infection in Anopheles gambiae. Science 2011, 332:855-858.
79. Liévin-Le Moal V., Servin A.L. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin. Microbiol. Rev. 2014, 27:167-199.
80. Mashburn L.M., et al. Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo coculture. J. Bacteriol. 2005, 187:554-566.
81. Stecher B., et al. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:1269-1274.
82. Ho P.L., et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS ONE 2011, 6:e17989.
83. Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 2010, 13:558-564.
84. Zhang L., et al. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob. Agents Chemother. 2013, 57:3659-3666.
85. Sommer M.O.a., et al. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 2009, 325:1128-1131.
86. Daniels J.B., et al. Molecular epidemiology of blaCMY-2 plasmids carried by Salmonella enterica and Escherichia coli isolates from cattle in the Pacific Northwest. Appl. Environ. Microbiol. 2007, 73:8005-8011.
87. Lundquist P.D., Levin B.R. Transitory derepression and the maintenance of conjugative plasmids. Genetics 1986, 113:483-497.
88. Klümper U., et al. Broad host range plasmids can invade an unexpectedly diverse fraction of a soil bacterial community. ISME J. 2015, 9:934-945.
89. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob. Agents Chemother. 2009, 53:2227-2238.
90. Heuer H., et al. Variation in permissiveness for broad-host-range plasmids among genetically indistinguishable isolates of Dickeya sp. from a small field plot. FEMS Microbiol. Ecol. 2010, 73:190-196.
91. Thomas C.M., Nielsen K.M. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat. Rev. Microbiol. 2005, 3:711-721.
92. Sørensen S.J., et al. Studying plasmid horizontal transfer in situ: a critical review. Nat. Rev. Microbiol. 2005, 3:700-710.
93. De Gelder L., et al. Plasmid donor affects host range of promiscuous IncP-1beta plasmid pB10 in an activated-sludge microbial community. Appl. Environ. Microbiol. 2005, 71:5309-5317.
94. Cazer C.L., et al. Use of pharmacokinetic modeling to assess antimicrobial pressure on enteric bacteria of beef cattle fed chlortetracycline for growth promotion, disease control, or treatment. Foodborne Pathog. Dis. 2014, 11:403-411.
95. Cantón R., Ruiz-Garbajosa P. Co-resistance: an opportunity for the bacteria and resistance genes. Curr. Opin. Pharmacol. 2011, 11:477-485.
96. Kumar A., Schweizer H.P. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv. Drug Deliv. Rev. 2005, 57:1486-1513.
97. Martinez J.L., Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 2002, 15:647-679.
98. Hafkin J.S., et al. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J. Viral Hepat. 2014, 21:288-296.
99. Skinner-Adams T.S., et al. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol. 2008, 24:264-271.
100. Mina M.J., et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015, 348:694-699.